Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.43 |
| ▸ | GSR | P00390 | 2/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Penicillamine SCHEMBL21768465 | 1.00 | PTGS1 (0.67) | PTGS1ALDH1A1MAPTSLC7A11GSR | |
| Penicillamine SCHEMBL6333581 | 1.00 | PTGS1 (0.67) | PTGS1ALDH1A1MAPTSLC7A11GSR | |
| Penicillamine SCHEMBL22124996 | 0.85 | PTGS1 (0.72) | PTGS1ALDH1A1MAPTSLC7A11GSR | |
| Dl-Penicillamine SCHEMBL22124997 | 0.85 | PTGS1 (0.72) | PTGS1ALDH1A1MAPTSLC7A11GSR | |
| Dl-Penicillamine SCHEMBL4261009 | 0.85 | PTGS1 (0.72) | PTGS1ALDH1A1MAPTSLC7A11GSR | |
| Penicillamine SCHEMBL7170074 | 0.85 | PTGS1 (0.72) | PTGS1ALDH1A1MAPTSLC7A11GSR | |
| Glutamic Acid SCHEMBL4261156 | 0.84 | GRM8 (0.64) | PTGS1ALDH1A1MAPTGSRGRM8 | |
| Penicillamine SCHEMBL11222229 | 0.83 | PTGS1 (0.69) | PTGS1ALDH1A1MAPTSLC7A11GSR | |
| Dl-Penicillamine SCHEMBL16011677 | 0.82 | ALDH1A1 (0.62) | PTGS1ALDH1A1MAPTGSRCYP1A2 | |
| Penicillamine SCHEMBL16011676 | 0.82 | ALDH1A1 (0.62) | PTGS1ALDH1A1MAPTGSRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE38828-E1 | Parevins and tachytegrins | INTRABIOTICS PHARMACEUTICALS, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-20020147301-A1 | Parevins and tachytegrins | INTRABIOTICS PHARMACEUTICALS, INC. | 2002-10-10 | — | — | US | disclosed |
| US-6307016-B1 | BROAD-SPECTRUM ANTIMICROBIAL PEPTIDES EFFECTIVE AGAINST A WIDE VARIETY OF MICROBES, INCLUDING BACTERIA; ANTIBIOTIC PEPTIDES | INTRABIOTICS PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | disclosed |
| EP-0836617-A4 | PAREVINS AND TACHYTEGRINS | INTRABIOTICS PHARMACEUTICALS (US) | 2000-06-28 | — | — | EP | disclosed |
| EP-0836617-A1 | PAREVINS AND TACHYTEGRINS | Intrabiotics Pharmaceuticals, Incorporated (US) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997002287-A1 | PAREVINS AND TACHYTEGRINS | INTRABIOTICS PHARMACEUTICALS, INCORPORATED (US) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147301-A1 | Parevins and tachytegrins | ANPEP, TAC3, PROKR1 | PTGS1 1921/4885ALDH1A1 4822/4885MAPT 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.